{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:27:17Z","timestamp":1790425637599,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T00:00:00Z","timestamp":1465257600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"to-BBB Technologies BV"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s00415-016-8183-3","type":"journal-article","created":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T10:06:58Z","timestamp":1465294018000},"page":"1641-1651","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse"],"prefix":"10.1007","volume":"263","author":[{"given":"Peter Joseph","family":"Jongen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Stavrakaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Voet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin","family":"Hoogervorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"van Munster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim H.","family":"Linssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovicus G.","family":"Sinnige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim I.","family":"Verhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo H.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruud","family":"van der Kruijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freek","family":"Verheul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Boringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Heerings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Gladdines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"L\u00f6nnqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,7]]},"reference":[{"issue":"1","key":"8183_CR1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","volume":"50","author":"WI McDonald","year":"2001","unstructured":"McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121\u2013127","journal-title":"Ann Neurol"},{"issue":"11","key":"8183_CR2","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1212\/WNL.0b013e3181d55ee9","volume":"74","author":"K Bejaoui","year":"2010","unstructured":"Bejaoui K, Rolak LA (2010) What is the risk of permanent disability from a multiple sclerosis relapse? Neurology 74(11):900\u2013902. doi: 10.1212\/WNL.0b013e3181d55ee9","journal-title":"Neurology"},{"issue":"12","key":"8183_CR3","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1111\/j.1468-1331.2005.01352.x","volume":"12","author":"F Sellebjerg","year":"2005","unstructured":"Sellebjerg F, Barnes D, Filippini G, Midgard R, Montalban X, Rieckmann P, Selmaj K, Visser LH, Sorensen PS (2005) EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol Off J Eur Fed Neurol Soc 12(12):939\u2013946. doi: 10.1111\/j.1468-1331.2005.01352.x","journal-title":"Eur J Neurol Off J Eur Fed Neurol Soc"},{"issue":"1","key":"8183_CR4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","volume":"96","author":"H Schacke","year":"2002","unstructured":"Schacke H, Docke WD, Asadullah K (2002) Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96(1):23\u201343","journal-title":"Pharmacol Ther"},{"key":"8183_CR5","unstructured":"Elixhauser A, Owens P (2006) Adverse Drug Events in US Hospitals, 2004: Statistical Brief #29. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD)"},{"issue":"8","key":"8183_CR6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1001\/archneur.1987.00520200007008","volume":"44","author":"R Troiano","year":"1987","unstructured":"Troiano R, Cook SD, Dowling PC (1987) Steroid therapy in multiple sclerosis. Point of view. Arch Neurol 44(8):803\u2013807","journal-title":"Arch Neurol"},{"issue":"6","key":"8183_CR7","first-page":"26","volume":"40","author":"L Bren","year":"2006","unstructured":"Bren L (2006) The importance of patient-reported outcomes\u2026it\u2019s all about the patients. FDA Consum 40(6):26\u201332","journal-title":"FDA Consum"},{"issue":"1","key":"8183_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1365-2133.2007.07950.x","volume":"157","author":"L Fardet","year":"2007","unstructured":"Fardet L, Flahault A, Kettaneh A, Tiev KP, Genereau T, Toledano C, Lebbe C, Cabane J (2007) Corticosteroid-induced clinical adverse events: frequency, risk factors and patient\u2019s opinion. Br J Dermatol 157(1):142\u2013148. doi: 10.1111\/j.1365-2133.2007.07950.x","journal-title":"Br J Dermatol"},{"issue":"3","key":"8183_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1600-0609.2009.01265.x","volume":"83","author":"JA Guidry","year":"2009","unstructured":"Guidry JA, George JN, Vesely SK, Kennison SM, Terrell DR (2009) Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. Eur J Haematol 83(3):175\u2013182. doi: 10.1111\/j.1600-0609.2009.01265.x","journal-title":"Eur J Haematol"},{"issue":"6","key":"8183_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/1352458513508835","volume":"20","author":"C Ramo-Tello","year":"2014","unstructured":"Ramo-Tello C, Grau-Lopez L, Tintore M, Rovira A, RamioiTorrenta L, Brieva L, Cano A, Carmona O, Saiz A, Torres F, Giner P, Nos C, Massuet A, Montalban X, Martinez-Caceres E, Costa J (2014) A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Mult Scler 20(6):717\u2013725. doi: 10.1177\/1352458513508835","journal-title":"Mult Scler"},{"issue":"6","key":"8183_CR11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1177\/1352458514531088","volume":"20","author":"J Chataway","year":"2014","unstructured":"Chataway J (2014) Oral versus intravenous steroids in multiple sclerosis relapses\u2014a perennial question? Mult Scler 20(6):643\u2013645. doi: 10.1177\/1352458514531088","journal-title":"Mult Scler"},{"key":"8183_CR12","first-page":"1","volume":"2","author":"Act Sport MoHWa Dutch Medical Research Involving Human Subjects, (WMO)","year":"1999","unstructured":"Act Sport MoHWa Dutch Medical Research Involving Human Subjects, (WMO) (1999) International Publication Series Health. Welfare and Sport 2:1\u201334","journal-title":"Welfare and Sport"},{"issue":"1","key":"8183_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/WNF.0b013e3182764f91","volume":"36","author":"V Shaygannejad","year":"2013","unstructured":"Shaygannejad V, Ashtari F, Alinaghian M, Norouzi R, Salari M, Fatehi F (2013) Short-term safety of pulse steroid therapy in multiple sclerosis relapses. Clin Neuropharmacol 36(1):1\u20133. doi: 10.1097\/WNF.0b013e3182764f91","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"8183_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/09638280701256868","volume":"30","author":"K Wynia","year":"2008","unstructured":"Wynia K, Middel B, van Dijk JP, de Ruiter H, de Keyser J, Reijneveld SA (2008) The Multiple Sclerosis impact Profile (MSIP). Development and testing psychometric properties of an ICF-based health measure. Disabil Rehabil 30(4):261\u2013274. doi: 10.1080\/09638280701256868","journal-title":"Disabil Rehabil"},{"issue":"14","key":"8183_CR15","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/09638280701476193","volume":"30","author":"K Wynia","year":"2008","unstructured":"Wynia K, Middel B, de Ruiter H, van Dijk JP, de Keyser JH, Reijneveld SA (2008) Stability and relative validity of the Multiple Sclerosis Impact Profile (MSIP). Disabil Rehabil 30(14):1027\u20131038","journal-title":"Disabil Rehabil"},{"issue":"11","key":"8183_CR16","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444\u20131452","journal-title":"Neurology"},{"issue":"9997","key":"8183_CR17","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/S0140-6736(15)61137-0","volume":"386","author":"E Page Le","year":"2015","unstructured":"Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Deburghgraeve V, Coustans M, Edan G (2015) Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet 386(9997):974\u2013981. doi: 10.1016\/S0140-6736(15)61137-0","journal-title":"Lancet"},{"issue":"3","key":"8183_CR18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1615\/CritRevImmunol.v29.i3.50","volume":"29","author":"F Luhder","year":"2009","unstructured":"Luhder F, Reichardt HM (2009) Traditional concepts and future avenues of glucocorticoid action in experimental autoimmune encephalomyelitis and multiple sclerosis therapy. Crit Rev Immunol 29(3):255\u2013273","journal-title":"Crit Rev Immunol"},{"issue":"5","key":"8183_CR19","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1136\/adc.2003.041541","volume":"90","author":"FA Stuart","year":"2005","unstructured":"Stuart FA, Segal TY, Keady S (2005) Adverse psychological effects of corticosteroids in children and adolescents. Arch Dis Child 90(5):500\u2013506. doi: 10.1136\/adc.2003.041541","journal-title":"Arch Dis Child"},{"issue":"6","key":"8183_CR20","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1046\/j.1365-2265.1996.8690878.x","volume":"45","author":"WF Kelly","year":"1996","unstructured":"Kelly WF, Kelly MJ, Faragher B (1996) A prospective study of psychiatric and psychological aspects of Cushing\u2019s syndrome. Clin Endocrinol 45(6):715\u2013720","journal-title":"Clin Endocrinol"},{"issue":"1","key":"8183_CR21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00001813-199502000-00002","volume":"6","author":"PJ Koehler","year":"1995","unstructured":"Koehler PJ (1995) Use of corticosteroids in neuro-oncology. Anticancer Drugs 6(1):19\u201333","journal-title":"Anticancer Drugs"},{"issue":"3","key":"8183_CR22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0049-0172(05)80039-3","volume":"23","author":"BL Weusten","year":"1993","unstructured":"Weusten BL, Jacobs JW, Bijlsma JW (1993) Corticosteroid pulse therapy in active rheumatoid arthritis. Semin Arthritis Rheum 23(3):183\u2013192","journal-title":"Semin Arthritis Rheum"},{"key":"8183_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515617248","author":"R Yamasaki","year":"2015","unstructured":"Yamasaki R, Matsushita T, Fukazawa T, Yokoyama K, Fujihara K, Ogino M, Yokota T, Miyamoto K, Niino M, Nomura K, Tomioka R, Tanaka M, Kawachi I, Ohashi T, Kaida KI, Matsui M, Nakatsuji Y, Ochi H, Fukaura H, Kanda T, Nagaishi A, Togo K, Mizusawa H, Murai H, Kira JI (2015) Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica. Mult Scler. doi: 10.1177\/1352458515617248","journal-title":"Mult Scler"},{"key":"8183_CR24","doi-asserted-by":"publisher","first-page":"w13783","DOI":"10.4414\/smw.2013.13783","volume":"143","author":"C Lienert","year":"2013","unstructured":"Lienert C, Schawalder G, Findling O, Kamm CP, Humpert S, Mugglin A, Mathis J, Sturzenegger M, Mattle HP (2013) Tolerance of intravenous methylprednisolone for relapse treatment in demyelinating CNS disease. Swiss Med Wkly 143:w13783. doi: 10.4414\/smw.2013.13783","journal-title":"Swiss Med Wkly"},{"issue":"3","key":"8183_CR25","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O\u2019Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stuve O, Waubant E, Polman CH (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83(3):278\u2013286. doi: 10.1212\/WNL.0000000000000560","journal-title":"Neurology"},{"issue":"3","key":"8183_CR26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/art.21984","volume":"55","author":"JR Curtis","year":"2006","unstructured":"Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, Kovac SH, Spettell CM, Saag KG (2006) Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 55(3):420\u2013426. doi: 10.1002\/art.21984","journal-title":"Arthritis Rheum"},{"key":"8183_CR27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12883-015-0450-x","volume":"15","author":"O Caster","year":"2015","unstructured":"Caster O, Edwards IR (2015) Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses. BMC Neurol 15:206. doi: 10.1186\/s12883-015-0450-x","journal-title":"BMC Neurol"},{"issue":"4","key":"8183_CR28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000382130","volume":"44","author":"T Kalincik","year":"2015","unstructured":"Kalincik T (2015) Multiple Sclerosis relapses: epidemiology, outcomes and management. A systematic review. Neuroepidemiology 44(4):199\u2013214. doi: 10.1159\/000382130","journal-title":"Neuroepidemiology"},{"key":"8183_CR29","doi-asserted-by":"publisher","first-page":"351416","DOI":"10.1155\/2015\/351416","volume":"2015","author":"M Asano","year":"2015","unstructured":"Asano M, Hawken K, Turpin M, Eitzen A, Finlayson M (2015) The lived experience of multiple sclerosis relapse: how adults with multiple sclerosis processed their relapse experience and evaluated their need for postrelapse care. Mult Scler Int 2015:351416. doi: 10.1155\/2015\/351416","journal-title":"Mult Scler Int"},{"issue":"1","key":"8183_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2165\/11592160-000000000-00000","volume":"5","author":"M Oleen-Burkey","year":"2012","unstructured":"Oleen-Burkey M, Castelli-Haley J, Lage MJ, Johnson KP (2012) Burden of a multiple sclerosis relapse: the patient\u2019s perspective. Patient 5(1):57\u201369. doi: 10.2165\/11592160-000000000-00000","journal-title":"Patient"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-016-8183-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-016-8183-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-016-8183-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T15:52:57Z","timestamp":1498319577000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-016-8183-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,7]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["8183"],"URL":"https:\/\/doi.org\/10.1007\/s00415-016-8183-3","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,7]]}}}